Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Palisade Bio (PALI) EBT Margin (2016 - 2025)

Palisade Bio (PALI) has disclosed EBT Margin for 14 consecutive years, with 58540.0% as the latest value for Q3 2025.

  • On a quarterly basis, EBT Margin changed N/A to 58540.0% in Q3 2025 year-over-year; TTM through Sep 2025 was 143350.0%, a N/A change, with the full-year FY2023 number at 5234.0%, changed N/A from a year prior.
  • EBT Margin was 58540.0% for Q3 2025 at Palisade Bio, down from 142250.0% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 231100.0% in Q1 2025 to a low of 1011.6% in Q1 2023.
  • A 3-year average of 86218.47% and a median of 58540.0% in 2025 define the central range for EBT Margin.
  • Biggest YoY gain for EBT Margin was 3310025bps in 2021; the steepest drop was 3310025bps in 2021.
  • Palisade Bio's EBT Margin stood at 213.97% in 2021, then plummeted by -573bps to 1011.6% in 2023, then skyrocketed by 5887bps to 58540.0% in 2025.
  • Per Business Quant, the three most recent readings for PALI's EBT Margin are 58540.0% (Q3 2025), 142250.0% (Q2 2025), and 231100.0% (Q1 2025).